Novo Nordisk disclosed it is discontinuing all cell therapy R&D, eliminating roughly 250 roles and ending programs across Parkinson’s, chronic heart failure and a Type 1 diabetes program as part of a companywide reorganization. The move reflects a strategic pivot toward obesity and metabolic franchises and follows recent asset sales by the company. In parallel, Bristol‑Myers Squibb agreed to acquire Orbital for $1.5 billion to add in‑vivo cell therapy capabilities, signaling continued M&A to secure cell‑engineering platforms even as some large pharmas retrench.